Vogenx joins the IPO queue to fund phase 2-stage metabolic drug July 16, 2026Posted inBiotechnology Vogenx has joined the growing queue for the Nasdaq, as the metabolic biotech eyes an IPO to fund its SGLT1 inhibitor. Post navigation Previous Post Trinh and Ryu Win DOW Funding for Fungal Biotech ResearchNext PostProgramming Fracture Resistance in Metamaterials through Elastic Instability Design
